NSCLC Incidence Declining, Except in Stage I Disease
— Increased lung cancer screening may be responsible
“The overall incidence of non-small cell lung cancer (NSCLC) decreased from 2010 to 2017, with the incidence of stage IV disease falling, and stage I disease rising, researchers determined.”

Equal Access to Care May Eliminate Racial Disparities in Lung Cancer Outcomes
“Equal access to diagnostic services and immunotherapy could eliminate outcome disparities between Black and White patients with lung cancer, according to 2 new studies.”

Report details cancer burden facing Black patients in California
“Study shows why addressing the root causes of cancer disparities is essential to saving lives”

RET Inhibitors Show Promise for Chinese Patients With RET Fusion–Positive NSCLC
“RET inhibitors pralsetinib Gavreto) and selpercatinib (Retevmo) have already demonstrated significant efficacy in treating a broad patient population with tumors harboring RET fusions and mutations. Indeed, both RET inhibitors are approved for use in the United States for the treatment of patients with metastatic RET fusion–positive non–small cell lung cancer (NSCLC).”

Convenient Clinical Trial Locations, Research Staff Availability Mitigate Barriers to Trial Access, Survey Says
“Varying clinical trial site locations, offering more convenient times for follow-up, and improving research staff availability were some effective strategies to mitigate COVID-19–related patient concerns and to increase participation in international lung cancer clinical trials.”

Further Analyses Expand Upon Duration of Benefit With Sotorasib in KRAS G12C+ NSCLC
“As sotorasib (Lumakras) is the first agent to be FDA approved for the treatment of patients with KRAS G12C–mutant non–small cell lung cancer (NSCLC), there is a great deal of interest in the KRAS inhibitor and its potential benefit.”

Video:

Lyudmila Bazhenova, MD, Discusses Potential for Trials Featuring Combination IO/Targeted Therapy for EGFR Exon 20+ and Wild Type NSCLC

Considering the Role of NRG1 Fusions in Lung Cancer Management